Fungal pneumonia is a common disease in bottlenose dolphins (*Tursiops truncatus*), which is most commonly caused by *Aspergillus fumigatus* \[[@r15]\]. Various antifungals, such as flucytosine, itraconazole, voriconazole, and posaconazole are used for the treatment of respiratory fungal infection in cetaceans \[[@r2], [@r12]\]. In clinical treatment of cetaceans, hematological abnormalities (leukopenia, neutropenia, and thrombocytopenia) have been reported with some drugs including antifungal agents \[[@r6], [@r10]\]. Moreover, there are some reports about use of granulocyte colony stimulating factor (G-CSF) for the treatment of these side effects in cetaceans \[[@r10], [@r11]\].

Micafungin is used for the treatment of some types of fungal infections including *A. fumigatus* in humans. Some studies have indicated that micafungin has a high clinical efficacy and safety in the treatment of aspergillosis in humans \[[@r1], [@r8]\]; however, based on the European Medicines Agency report, associated side effects include elevated hepatic enzyme(s) levels and leukopenia \[[@r4]\]. The use of micafungin treatment and its side effects in bottlenose dolphins has not been previously reported, although it is used with the same dosage (3 mg/kg/day) in this species without side effects, including hematological abnormalities, in other facilities in Japan (personal communication). In this report, we describe our experience with a case of micafungin-induced decline of body temperature (BT) and leukopenia in an *A. fumigatus*-infected bottlenose dolphin, which showed a good response to G-CSF therapy.

An adult female bottlenose dolphin, estimated to be 13 to 16 years old and weighing 240 kg, was housed in the Port of Nagoya Public Aquarium (PNPA). On day 1 of the disease course, the animal showed lethargy, sputum discharge, and bad breath. Subsequently, a blood test was performed, even though the animal's BT was in the normal range. The animal showed non-specific signs of inflammation, including elevation of white blood cells (WBCs), segmented neutrophils (SEGs), and fibrinogen (FIB) and subsequently developed a fever ([Fig. 1](#fig_001){ref-type="fig"}Fig. 1.Clinical change in body temperature (BT) (°C), white blood cells (WBCs) (cells/*µl*), segmented neutrophils (SEGs) (cells/*µl*) and fibrinogen (FIB) (mg/d*l*) during medications with side effects, clinical symptoms, and the results of clinical examinations in a bottlenose dolphin (*Tursiops truncatus*). The red squares with a V, the yellow square with an M, the blue square with an A, and the green squares with a G indicate periods of treatment with voriconazole (5 mg/kg/day, orally), micafungin (3 mg/kg/day, intravenously), amphotericin B (0.2−0.4 mg/kg/day, inhalation), and granulocyte colony stimulating factor (G-CSF) (2.5 *µ*g/kg/day, intramuscular) administration, respectively. The thin black arrows indicate antibiotic administration (ERFX: enrofloxacin, LVFX: levofloxacin, AMK: amikacin, AMK-IH: amikacin-inhalation, FOM: fosfomycin). The thick black arrows indicate side effects (decline of body temperature (BT), leukopenia). The gray wave profile indicates the withdrawal of clinical symptoms (lethargy, sputum, bad breath). This profile was based on the subjective assessment data (medical or training records, memories of a veterinarian and dolphin trainers). The green solid and outlined circles indicate the time points at which blowhole fungal cultures were positive or negative for *Aspergillus fumigatus*, respectively. The red outlined circles indicate the blood cultures are negative.). Since *A. fumigatus* was isolated from the blowhole, as described below, voriconazole (5 mg/kg/day, orally; VFEND, Pfizer Japan, Tokyo, Japan) and micafungin (3 mg/kg/day, intravenously; Fungurd, Astellas Pharma, Tokyo, Japan) were administered to the animal on days 2--5, 27--29, 41, and 49 and on days 11--20, respectively. This therapy was combined with amphotericin B (0.2--0.4 mg/kg/day, inhalation; FUNGIZON, Bristol-Myers Squibb, Tokyo, Japan) on days 7--37 ([Figs. 1](#fig_001){ref-type="fig"} and[2](#fig_002){ref-type="fig"}) using an inhaler device (INH001, Taylor's Pharmacy, Orlando, FL, U.S.A.) made specifically for dolphins \[[@r3]\]. After administration of micafungin, decline of BT and leukopenia was observed. Therefore, the animal was treated with G-CSF (2.5 *µ*g/kg/day, intramuscular; Filgrastim, Mochida Pharmaceutical, Tokyo, Japan) on days 23--25 (first therapy) and days 31--34 (second therapy) for the purpose of stimulating blood cell production in the bone marrow ([Figs. 1](#fig_001){ref-type="fig"} and[2](#fig_002){ref-type="fig"}).

BT was measured rectally using a digital clinical thermometer with a probe, as described previously \[[@r7]\]. Blood samples were obtained from the fluke vessels through a 21-gauge butterfly needle and 10-m*l* disposable syringe. The blood was collected in ethylene diamine tetra-acetic acid (EDTA) −2K tubes, sodium heparin-coated tubes, 3.2% sodium citrate tubes, and blood culture bottles (BACT/ALERT FA PLUS, BACT/ALERT FN PLUS, bioMérieux Japan, Tokyo, Japan) for performing a complete blood count, serum biochemistry or measurement of plasma concentration of voriconazole, measurement of FIB, and blood culture, respectively. Blood smears were stained with May-Gruenwald's and Giemsa's stain solution for obtaining the differential WBCs count. Blowhole swab samples on days 1, 5, 9, 15, 23, 37, 45, and 53 were cultured on Sabouraud agar plates at 37°C for 48 hr. All examinations except measurement of plasma concentration of voriconazole and blood culture were carried out at the PNPA. The plasma concentrations of voriconazole on days 6, 13, 21, 30, 37, 41, 42, 49, 50, and 53 were measured by a clinical testing company (SRL, Tokyo, Japan) through high performance liquid chromatography (HPLC) (HPLC SYSTEM, 10Ave series, Shimadzu, Hamamatsu, Japan). The blood cultures on days 9, 15, 23, 26, 35, and 45 were conducted with BACT/ALERT 3D (bioMérieux Japan, Tokyo, Japan) by a clinical testing company (Health Sciences Research Institute, Yokohama, Japan). Bacterial species identification and drug sensitivity tests on days 1, 5, 9, 15, 23, 37, 45, and 53 were also conducted by the same company, together with the blood cultures.

*A. fumigatus* was isolated on days 1, 5, 9, 15, 23, and 37 ([Fig. 1](#fig_001){ref-type="fig"}). The fungal species was identified based on colony morphology \[[@r16]\] at the PNPA. Some bacteria including *Pseudomonas aeruginosa* were isolated from the blowhole swab samples, and antibiotics were selected according to the results of the drug sensitivity tests ([Table 1](#tbl_001){ref-type="table"}Table 1.Summary of administered antibiotics and identity of bacteria isolated from blowhole swab samplesDayAntibiotic^a)^Dosage (mg/kg)Frequency and route^c)^Bacterial isolation^e)^5, 10Enrofloxacin5.0SID, IM*V. fluvialis*, *S. intermedius* (1)\
*V. fluvialis*, *α-Streptococcus* (5)\
*A. faecalis*, *α-Streptococcus* (9)\
*A. caviae*, *P. aeruginosa* (15, 23)\
*α-Streptococcus*, *P. aeruginosa* (37)\
*A. caviae*, *P. aeruginosa* (45)\
*Corynebacterium sp*, *P. aeruginosa* (53)7--9, 39--52Levofloxacin7.0SID, PO12--38Amikacin11.0SID, IM16--36Amikacin^b)^0.8--0.9SID, IH^d)^24--30Fosfomycin20.0BID, IVa) Enrofloxacin: Baytril one-shot, Bayer Yakuhin, Osaka, Japan; Levofloxacin: CRAVIT, DAIICHI SANKYO COMPANY, Tokyo, Japan; Amikacin: AMIKACIN SULFATE, Fuji Pharma, Tokyo, Japan; Fosfomycin: FOSMICIN, Meiji Seika Pharma, Tokyo, Japan; b) 4-fold diluted amikacin with saline was used; c) SID: once a day; BID: twice a day; IM: intramuscular administration; PO: oral administration; IH: inhalation; IV: intravenous administration; d) inhaler device made specifically for dolphins \[[@r3]\] was used; e) Number in parenthesis indicates the day of bacterial isolation; *V. fluvialis*: *Vibrio fluvialis*; *S. intermedius*: *Staphylococcus intermedius*; *A. faecalis*: *Alcaligenes faecalis*; *A. caviae*: *Aeromonas caviae*; *P. aeruginosa*: *Pseudomonas aeruginosa*.). The blood cultures were all negative ([Fig. 1](#fig_001){ref-type="fig"}).

The highest BT of the dolphin (38.8°C) was recorded on day 6. A decline of BT (36.0°C) was initially recorded on day 13, with lowest BT (34.2°C) on day 20, two and nine days after the first administration of micafungin, respectively. After stopping micafungin administration, there was no further decline of BT; subsequently, the BT increased to 35.7°C on day 21. Although the BT showed a transient increase to 38.2°C on day 24 during the first G-CSF therapy, it decreased gradually to 36.7°C by day 53, which was within normal range for this animal ([Fig. 1](#fig_001){ref-type="fig"}).

A decrease in WBCs and SEGs was observed on day 22, eleven days after the first administration of micafungin, with lowest values of 600 cells/*µl* and 67 cells/*µl* on days 24 and 25, respectively. Six days after the first administration of G-CSF (day 29), WBCs and SEGs increased to 7,300 cells/*µl* and 4,446 cells/*µl*, respectively, which were within normal ranges for this animal; however, since both values showed a subsequent decline to 3,600 cells/*µl* and 773 cells/*µl* on days 31 and 33, respectively, the second G-CSF therapy was conducted (days 31--34). Thereafter, WBCs and SEGs showed a transient increase to 30,400 cells/*µl* and 23,074 cells/*µl* on day 36 and decreased gradually by day 50 to 6,700 cells/*µl* and 4,844 cells/*µl*, respectively, which were within normal ranges for this animal ([Fig. 1](#fig_001){ref-type="fig"}). After starting micafungin administration, a hepatic enzyme, glutamic oxaloacetic transaminase (GOT) increased significantly and attained maximum level (412 IU/*l*) on day 21 ([Fig. 2](#fig_002){ref-type="fig"}Fig. 2.Change in glutamic oxaloacetic transaminase (GOT) levels (IU/*l*) and voriconazole concentrations (*µ*g/m*l*) in blood during drug therapy with side effects in a bottlenose dolphin (*Tursiops truncatus*). The red squares with a V, the yellow square with an M, the blue square with an A, and the green squares with a G indicate periods of treatment with voriconazole (5 mg/kg/day, orally), micafungin (3 mg/kg/day, intravenously), amphotericin B (0.2−0.4 mg/kg/day, inhalation), and granulocyte colony stimulating factor (G-CSF) (2.5 *µ*g/kg/day, intramuscular) administration, respectively. The thin black arrows indicate antibiotic administration (ERFX: enrofloxacin, LVFX: levofloxacin, AMK: amikacin, AMK-IH: amikacin-inhalation, FOM: fosfomycin). The thick black arrows indicate side effects (decline of body temperature (BT), leukopenia).). The plasma concentrations of voriconazole on days 6, 13, 21, 30, 37, 41, 42, 49, 50, and 53 were 8.55, 5.09, 2.30, 12.94, 5.68, 3.36, 6.99, 2.79, 6.16, and 4.30 *µ*g/m*l*, respectively ([Fig. 2](#fig_002){ref-type="fig"}).

Various antifungals are used for the treatment of respiratory fungal infection in cetaceans \[[@r2], [@r12]\]. To our knowledge, there are no previous reports of the use of micafungin for the treatment of fungal infection in cetaceans. In this report, micafungin was selected for treatment because there were no improvements in the BT, blood test results (WBCs, SEGs, and FIB), clinical symptoms, and blowhole fungal culture after voriconazole administration ([Fig. 1](#fig_001){ref-type="fig"}), a commonly used treatment for fungal infection in cetaceans \[[@r2], [@r14]\]. Decline of BT and leukopenia were only observed after micafungin administration ([Figs. 1](#fig_001){ref-type="fig"} and[2](#fig_002){ref-type="fig"}). These phenomena might be caused by micafungin but not by voriconazole because they were not observed immediately post voriconazole administration: plasma concentration of voriconazole (8.55 *µ*g/m*l*) ([Fig. 2](#fig_002){ref-type="fig"}) was above the safe range (2 to 4 *µ*g/m*l*) in this species \[[@r5]\], although the cause or action mechanism of these side effects remains unknown. The first decline of BT was observed on day 13, when the plasma concentration of voriconazole was 5.09 *µ*g/m*l* ([Fig. 2](#fig_002){ref-type="fig"}), which exceeded both the safe range and upper limit (5 *µ*g/m*l*), increasing the risk of hepatic side effects in this species \[[@r5]\]. However, we observed no other side effects including anorexia or visual abnormalities which are the main known adverse effects of voriconazole \[[@r5], [@r13]\]. Moreover, there was no further decline of BT after withdrawing micafungin ([Figs. 1](#fig_001){ref-type="fig"} and[2](#fig_002){ref-type="fig"}). With regard to the GOT levels, a maximum level was observed on day 21, just after micafungin administration, rather than after voriconazole administration ([Fig. 2](#fig_002){ref-type="fig"}). Ferrier *et al*. \[[@r5]\] reported that GOT level showed a possible relationship with voriconazole concentration in bottlenose dolphins; however, at the time of the assay, the plasma concentration of voriconazole was within the safe range (2.30 *µ*g/m*l*) ([Fig. 2](#fig_002){ref-type="fig"}). In our study, the plasma concentration of voriconazole (maximum level, 12.94 *µ*g/m*l*) ([Fig. 2](#fig_002){ref-type="fig"}) showed a transient increase above the safe range during the treatment period. However, a previous report had indicated that a plasma concentration of voriconazole of 9 to 12 *µ*g/m*l* was tolerable for this species \[[@r13]\]. Furthermore, there were no other side effects including anorexia, visual abnormalities, and further elevation of the GOT levels during the treatment ([Fig. 2](#fig_002){ref-type="fig"}). Focusing on the differential WBCs count in this case, eosinophilia and lymphocytosis were also seen prominently with highest values of 4,101 cells/*µl* and 2,365 cells/*µl* on days 13 and 14, respectively, during micafungin administration (data not shown). These phenomena might be caused by a hypersensitive reaction to micafungin. Similar reactions to sulfonamide have been reported in killer whale (*Orcinus orca*), dogs, and humans with neutropenia and thrombocytopenia \[[@r10]\], as well as to vancomycin in humans with neutropenia and eosinophilia \[[@r9]\]. Furthermore, the values of both the eosinophils and of the lymphocytes decreased to normal ranges for this animal after withdrawing micafungin. It is likely that the observed decline of BT and leukopenia in this animal was related to the side effects of micafungin rather than to those of voriconazole and other administered drugs.

Ultimately, this animal recovered from its *A. fumigatus* infection owing to a combination therapy with voriconazole (systemic) and amphotericin B (topical). Treatment success was judged from normalization of the BT, blood test results (WBCs, SEGs, and FIB), and clinical symptoms and the disappearance of *A. fumigatus* from the blowhole ([Fig. 1](#fig_001){ref-type="fig"}). It was very difficult to evaluate the efficacy of micafungin because it was discontinued post appearance of the side effects. However, we can say for sure that it is very important to monitor the BT and the hematological panels regularly during micafungin administration. Moreover, the effectivity of G-CSF for treating drug-induced leukopenia in cetaceans, as described previously \[[@r10]\], was reaffirmed through this case.

In conclusion, we present the first report of a micafungin-induced decline of BT and leukopenia in a bottlenose dolphin.
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